UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gene aberrations for precision medicine against lung adenocarcinoma

Cancer science, 2016-06, Vol.107 (6), p.713-720

2016

Volltextzugriff (PDF)

Top 10 reasons why you must learn onco-nephrology

Japanese journal of clinical oncology, 2016-01, Vol.46 (1), p.2-3

Kunitoh, Hideo

2016

Volltextzugriff (PDF)

Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry

Japanese journal of clinical oncology, 2020-10, Vol.50 (11), p.1246-1253

2020

Volltextzugriff (PDF)

Promises and challenges of immuno-oncology from a clinical perspective

Japanese journal of clinical oncology, 2018-02, Vol.48 (2), p.101-102

Kunitoh, Hideo

2018

Volltextzugriff (PDF)

Association between tumor response to systemic therapy and patient-reported disease symptoms

Japanese journal of clinical oncology, 2022-12, Vol.52 (12), p.1423-1429

2022

Volltextzugriff (PDF)

Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

Clinical cancer research, 2006-07, Vol.12 (13), p.3915-3921

2006

Volltextzugriff (PDF)

Message from the Editor-in-Chief

Japanese journal of clinical oncology, 2024-01, Vol.54 (1), p.1-3

Kunitoh, Hideo

2024

Volltextzugriff (PDF)

A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population

Nature genetics, 2012-08, Vol.44 (8), p.900-903

2012

Volltextzugriff (PDF)

The Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: past activities, current status and future direction

Japanese journal of clinical oncology, 2017-03, Vol.47 (3), p.194-199

2017

Volltextzugriff (PDF)

Regulatory Nexus of Synthesis and Degradation Deciphers Cellular Nrf2 Expression Levels

Molecular and Cellular Biology, 2013-06, Vol.33 (12), p.2402-2412

2013

Volltextzugriff (PDF)

Message from the Editor-in-Chief

Japanese journal of clinical oncology, 2023-01, Vol.53 (1), p.1-3

Kunitoh, Hideo

2023

Volltextzugriff (PDF)

High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients

Cancer science, 2006-07, Vol.97 (7), p.642-648

2006

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-10, Vol.23 (28), p.6829-6837

2005

Volltextzugriff (PDF)

Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer

Japanese journal of clinical oncology, 2023-01, Vol.53 (2), p.153-160

2023

Volltextzugriff (PDF)

Publishing inconvenient data

Japanese journal of clinical oncology, 2022-05, Vol.52 (5), p.403-404

Kunitoh, Hideo

2022

Volltextzugriff (PDF)

Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)

Japanese journal of clinical oncology, 2022-07, Vol.52 (7), p.791-794

2022

Volltextzugriff (PDF)

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

Journal of clinical oncology, 2008-12, Vol.26 (34), p.5589-5595

2008

Volltextzugriff (PDF)

Message from the Editor-in-Chief

Japanese journal of clinical oncology, 2022-01, Vol.52 (1), p.1-2

Kunitoh, Hideo

2022

Volltextzugriff (PDF)

High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non‐small cell lung cancer

Thoracic cancer, 2019-10, Vol.10 (10), p.2006-2012

2019

Volltextzugriff (PDF)

Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: real-world data from Japan

Japanese journal of clinical oncology, 2019-01, Vol.49 (1), p.63-68

2019

Volltextzugriff (PDF)

Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)

Japanese journal of clinical oncology, 2019-06, Vol.49 (6), p.554-558

2019

Volltextzugriff (PDF)

Message from the Editor-in-Chief

Japanese journal of clinical oncology, 2021-01, Vol.51 (1), p.1-2

Kunitoh, Hideo

2021

Volltextzugriff (PDF)

A catastrophe caused by good intentions?

Japanese journal of clinical oncology, 2020-04, Vol.50 (4), p.347-348

Kunitoh, Hideo

2020

Volltextzugriff (PDF)

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy

Lung cancer (Amsterdam, Netherlands), 2015-09, Vol.89 (3), p.287-293

2015

Volltextzugriff (PDF)

Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer

Japanese journal of clinical oncology, 2019-02, Vol.49 (2), p.160-164

2019

Volltextzugriff (PDF)

1 – 25 von 242

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(232)
Mit Volltextzugriff
(232)

Publikationsform

Artikel
(242)

Sprache

Englisch
(231)
Japanisch
(60)

Erscheinungsjahr

n.n

Thema

Science & Technology
(168)
Life Sciences & Biomedicine
(165)
Humans
(149)
Oncology
(136)
Female
(108)
Male
(105)
Aged
(100)
Middle Aged
(95)
Adult
(81)
Lung Neoplasms - Drug Therapy
(76)
Biological And Medical Sciences
(64)
Medical Sciences
(64)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(60)
Lung Cancer
(43)
Pneumology
(42)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(40)
Lung Neoplasms - Genetics
(40)
Lung Neoplasms - Pathology
(40)
Tumors Of The Respiratory System And Mediastinum
(40)
Chemotherapy
(36)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Gene aberrations for precision medicine against lung adenocarcinoma

Top 10 reasons why you must learn onco-nephrology

Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry

Promises and challenges of immuno-oncology from a clinical perspective

Association between tumor response to systemic therapy and patient-reported disease symptoms

Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

Message from the Editor-in-Chief

A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population

The Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: past activities, current status and future direction

Regulatory Nexus of Synthesis and Degradation Deciphers Cellular Nrf2 Expression Levels

Message from the Editor-in-Chief

High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer

Publishing inconvenient data

Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

Message from the Editor-in-Chief

High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non‐small cell lung cancer

Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: real-world data from Japan

Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)

Message from the Editor-in-Chief

A catastrophe caused by good intentions?

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy

Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer

Suchergebnisse filtern